The publication of this infographic was funded by AstraZeneca, and is intended for US Healthcare Professionals. Expert opinions are shared in this program and may differ from the approved capivasertib (TRUQAP®) labeling. Please see full Prescribing Information, including Patient Information when making treatment decisions.
Glucose elevations with capivasertib were manageable in the CAPItello-291 trial: approximately 37% of patients had an any-grade increase in fasting glucose (FG) from baseline, with a median time to first occurrence of 15 days, and 0.6% of patients each had dose reductions and permanent discontinuations due to hyperglycemia. In a recent US real-world observational study in patients with metastatic breast cancer, both the occurrence of hyperglycemia and the requirement for antihyperglycemic medications were lower with capivasertib than with other PI3K/AKT pathway inhibitors.
The infographic also sets out practical steps to prevent, monitor, and treat hyperglycemia during capivasertib therapy: preparing proactively before Day 1, monitoring FG and counseling patients, starting or increasing metformin, withholding capivasertib until FG ≤160 mg/dL, following resume rules, and keeping patients on treatment. An illustrative example shows the recommended action at each FG level. Some key recommendations are based on expert panel consensus.
